Massivemarkets

LCTX

Lineage Cell Therapeutics, Inc.

NYSE American · usd

$0.8385+0.02 (+2.78%)
At close · 15-minute delayed
$0.8350-0.00 (-0.42%)
As of 7:30:02 PM EST on Nov 18, 2026 · After hours

Lineage Cell Therapeutics, Inc. (LCTX) trades at $0.8385 (+2.78%) as of 7:30:02 PM EST on Nov 18, 2026, -13.79% over the past month. Market cap is $206.36M, with 19.3 days to cover in short interest.

Stock performance

How Lineage Cell Therapeutics, Inc. (LCTX) stock has performed from one day to one year, with its 52-week range.

-0.36%
-$0.00 over 1D
$0.82$0.83$0.85$0.865:50 AM10:55 AM12:45 PM2:30 PM5:50 PM$0.84
1D
+2.78%
1W
-24.46%
1M
-13.79%
YTD
-49.79%
1Y
-50.96%
52-wk range
$0.77 – $1.99

Key statistics

Today's trading snapshot for LCTX: day range, open, previous close, volume and market cap.

Day range
$0.82 – $0.86
Open
$0.82
Prev close
$0.82
Volume
1.22M
Market cap
$206.36M
Shares out
252.95M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Lineage Cell Therapeutics, Inc.: P/E, P/S, P/B, ROE and more.

P/E
118.32
P/S
19.14
P/B
3.09
P/FCF
—
ROE
2.6%
ROA
1.8%
Debt/Equity
0.00
Div yield
0.00%

As of Nov 17, 2026

8-K filings

Material corporate events Lineage Cell Therapeutics, Inc. has disclosed to the SEC on Form 8-K.

  • Licensing agreementNov 12, 2026

    Under the License Agreement, NeuroAirmid and Lineage ... received an exclusive license under specified patent rights relating to neural stem cell compositions and methods to treat neurodegenerative disorders, and a nonexclusive license to associated technology, to develop, manufacture and commercialize licensed products.

  • Deal withdrawalJun 12, 2026

    On June 9, 2026, following comments to the application received by the Company from CIRM, the Company elected to withdraw its application for the CIRM Grant. The withdrawal of the application does not impact the Company's current and planned development of OPC1 in the ongoing DOSED clinical study.

  • Public offeringMar 11, 2026

    On March 11, 2026, Lineage Cell Therapeutics, Inc. (the "Company") filed with the U.S. Securities and Exchange Commission (the "SEC") a prospectus supplement dated March 11, 2026 relating to the offer and sale of the Company's common shares from time to time through or to B. Riley Securities, Inc. ("B. Riley"), pursuant to the sales agreement the Company entered into with B. Riley dated March 22, 2024. The Prospectus Supplement relates to the offer and sale of the Company's common shares under the Sales Agreement having an aggregate offering price of up to $60,000,000 (the "ATM Shares").

  • Partnership or collaborationNov 24, 2025

    In December 2021, Lineage Cell Therapeutics, Inc. entered into a collaboration and license agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. (the 'Roche Agreement') under which our lead cell therapy program known as OpRegen® (also known as RG6501) is being developed for the treatment of ocular disorders, including geographic atrophy ('GA') secondary to age-related macular degeneration ('AMD').

  • Strategic initiativeAug 26, 2025

    The main objective of the RCA is for the parties to complete a preclinical phase achieving readiness to potentially progress to human clinical trials under one or more separate clinical agreements, representing a material advancement of Lineage's auditory neuronal cell transplant program.

LCTX short interest

How heavily LCTX is shorted: shares short, days to cover and average daily volume.

Days to cover
19.3
Short interest
24.35M
Avg volume
1.26M

As of · reported to FINRA twice monthly.

LCTX news

The latest news and headlines about Lineage Cell Therapeutics, Inc. (LCTX).

Frequently asked questions

What is the Lineage Cell Therapeutics, Inc. (LCTX) stock price today?

Lineage Cell Therapeutics, Inc. (LCTX) is trading at $0.8385 (+2.78% on the day) as of 7:30:02 PM EST on Nov 18, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Lineage Cell Therapeutics, Inc.?

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases.

What is the short interest in LCTX?

As of Oct 30, 2026, LCTX has 24.35M shares short and 19.3 days to cover.

What exchange is LCTX listed on?

Lineage Cell Therapeutics, Inc. (LCTX) trades on NYSE American in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

Build with AI

Build an analysis of LCTX with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a LCTX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.